Population pharmacokinetic-pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in topics with early Alzheimer's disease. In February 2018, the trial protocol was amended to supply up to five years of more remedy in an open up-label extensi